Article
Immunology
Sara Alosaimy, Kyle P. Murray, Evan J. Zasowski, Taylor Morrisette, Abdalhamid M. Lagnf, Thomas P. Lodise, Michael J. Rybak
Summary: This study aimed to evaluate the association between vancomycin AUC and clinical outcomes in MRSA cSSTIs, with results showing that achieving target AUC was significantly associated with timely clinical success (TCS), particularly important for high-risk patients.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Antigone Kotsaki, Nikolaos Tziolos, Theano Kontopoulou, Ioannis M. Koutelidakis, Styliani Symbardi, Vaughan Reed, Miriam O'Hare, Zoi Alexiou, Helen Sambatakou, Konstantinos Toutouzas, Karolina Akinosoglou, Malvina Lada, Evangelos J. Giamarellos-Bourboulis, Alasdair MacGowan
Summary: This study compared the effectiveness of oral minocycline plus rifampicin with linezolid in treating complicated skin and skin structure infections (cSSSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA). The results showed that oral minocycline plus rifampicin was non-inferior to linezolid, providing an alternative oral treatment option for cSSSI.
Review
Biotechnology & Applied Microbiology
Muhammad Waqas Saeed, Syed Wasif Gillani, Rana Kamran Mahmood, Prasanna Vippadapu, Mian Waqar Hussain, Hassaan Anwer Rathore
Summary: Ceftolozane/tazobactam showed higher clinical cure and microbiological eradication rates in complicated UTI, and was more effective in treating complicated urinary tract infections other than acute pyelonephritis compared to piperacillin/tazobactam.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Microbiology
Nadine Rouphael, Patricia Winokur, Michael C. Keefer, Jessica Traenkner, Ana Drobeniuc, Yohei Doi, Sonal Munsiff, Vance G. Fowler, Scott Evans, Randolph E. Oler, Bonifride Tuyishimire, Marina Lee, Varduhi Ghazaryan, Henry F. Chambers
Summary: Concerns over resistance and safety have been identified in the current treatment regimen for complicated urinary tract infections. Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.
Article
Gastroenterology & Hepatology
Anne Abildtrup Rode, Mahtab Chehri, Laura Rindom Krogsgaard, Kristine Klysner Heno, Anna Tolboll Svendsen, Iben Ribberholt, Morten Helms, Jorgen Engberg, Kristian Schonning, Michael Tvede, Christian Ostergaard Andersen, Ulrich Stab Jensen, Andreas Munk Petersen, Peter Bytzer
Summary: In comparison for recurrent Clostridioides difficile infection, the FMT group had a higher cure rate than the vancomycin or rectal bacteriotherapy group. Rectal bacteriotherapy and vancomycin performed similarly, but FMT with 1-3 infusions was superior to both. FMT may also reduce mortality compared to vancomycin.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Nimish Patel, Colleen Lowry, Daralyn Morgenson, Vaishali Shah, Nicholas Stornelli, Thomas P. Lodise
Summary: This retrospective cohort study compared real-world effectiveness outcomes of early-targeted fidaxomicin versus oral vancomycin for CDI treatment in hospitalized patients, and found that fidaxomicin potentially leads to better outcomes compared to vancomycin in this patient population.
Article
Pharmacology & Pharmacy
Wasan Katip, Peninnah Oberdorfer
Summary: This study found that a vancomycin AUC/MIC of >=400 mg·h/L was associated with significant differences in clinical and microbiological responses, but also increased the risk of nephrotoxicity. Adjusting vancomycin dosage to achieve the optimal AUC/MIC target ≥400 mg·h/L is crucial for the treatment of enterococcal infections.
Article
Immunology
Marin L. Schweizer, Kelly Richardson, Mary S. Vaughan Sarrazin, Michihiko Goto, Daniel J. Livorsi, Rajeshwari Nair, Bruce Alexander, Brice F. Beck, Michael P. Jones, Mireia Puig-Asensio, Daniel Suh, Madeline Ohl, Eli N. Perencevich
Summary: Among patients with methicillin-resistant Staphylococcus aureus bloodstream infections, switching to daptomycin is associated with lower 30-day mortality, especially when done within 3 days of initial vancomycin receipt. However, switching to daptomycin at any time during the first hospitalization did not significantly affect 30-day mortality.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Public, Environmental & Occupational Health
V. M. Eichel, K. Last, C. Bruhwasser, H. von Baum, M. Dettenkofer, T. Gotting, H. Grundmann, H. Guldenhoven, J. Liese, M. Martin, C. Papan, C. Sadaghiani, C. Wendt, G. Werner, N. T. Mutters
Summary: Vancomycin-resistant enterococci (VRE) infections cause a significant burden in healthcare settings, but knowledge about the epidemiology and outcomes of these infections remains fragmented. This study aimed to summarize recent research on VRE infections in hospitals, long-term care facilities, and nursing homes worldwide. The findings showed that VRE infections had a high incidence and mortality rate, but there was significant heterogeneity between regions and institutions. Moreover, the study highlighted the lack of standardized reporting of outcomes, as well as limited information on healthcare costs and state-of-the-art microbiological species identification methodology.
JOURNAL OF HOSPITAL INFECTION
(2023)
Article
Microbiology
Meng Lv, Ping Yang, Shengnan Zhang, Lingling Wang, Keming Sun, Libo Zhao
Summary: This study successfully developed a new population pharmacokinetic model of vancomycin in pediatric patients with SSTI and BJI using scavenged blood samples. Body weight was identified as a significant covariate on drug clearance and distribution volume. Dosing regimens of 75 mg/kg/day and 80 mg/kg/day were recommended for this specific population.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Review
Microbiology
Ilaria Cavallo, Alessandra Oliva, Rebecca Pages, Francesca Sivori, Mauro Truglio, Giorgia Fabrizio, Martina Pasqua, Fulvia Pimpinelli, Enea Gino Di Domenico
Summary: Acinetobacter baumannii is a major pathogen in vulnerable and critically ill patients, causing various infections with high mortality rates. Carbapenems have been the first choice for treatment, but widespread prevalence of carbapenem-resistant A. baumannii has led to the use of colistin as the main therapeutic option. However, high clinical failure rates have been reported for colistin monotherapy. Additionally, A. baumannii forms biofilms on medical devices, posing a significant treatment challenge.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Infectious Diseases
Pedro L. Gonzalez, Urania Rappo, Veronica Mas Casullo, Karthik Akinapelli, Jennifer S. McGregor, Jennifer Nelson, Michael Nowak, Sailaja Puttagunta, Michael W. Dunne
Summary: Nephrotoxicity rates were lower in patients treated with dalbavancin compared to those treated with intravenous vancomycin for at least 10 days, suggesting that dalbavancin may be less nephrotoxic than vancomycin when administered intravenously.
INFECTIOUS DISEASES AND THERAPY
(2021)
Review
Infectious Diseases
Shio-Shin Jean, I-Min Liu, Po-Chuen Hsieh, Dai-Huang Kuo, Yi-Lien Liu, Po-Ren Hsueh
Summary: Infections caused by MDR and XDR bacteria pose challenges for physicians in treatment decisions, and various antibiotics have been approved for treating these infections. However, evidence for the treatment of certain infections is still lacking.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Medicine, General & Internal
Urs Fischer, Masatoshi Koga, Daniel Strbian, Mattia Branca, Stefanie Abend, Sven Trelle, Maurizio Paciaroni, Goetz Thomalla, Patrik Michel, Krassen Nedeltchev, Leo H. Bonati, George Ntaios, Thomas Gattringer, Else-Charlotte Sandset, Peter Kelly, Robin Lemmens, P. N. Sylaja, Diana Aguiar de Sousa, Natan M. Bornstein, Zuzana Gdovinova, Takeshi Yoshimoto, Marjaana Tiainen, Helen Thomas, Manju Krishnan, Gek C. Shim, Christoph Gumbinger, Jochen Vehoff, Liqun Zhang, Kosuke Matsuzono, Espen Kristoffersen, Philippe Desfontaines, Peter Vanacker, Angelika Alonso, Yusuke Yakushiji, Caterina Kulyk, Dimitri Hemelsoet, Sven Poli, Ana Paiva Nunes, Nicoletta Caracciolo, Peter Slade, Jelle Demeestere, Alexander Salerno, Markus Kneihsl, Timo Kahles, Daria Giudici, Kanta Tanaka, Silja Raty, Rea Hidalgo, David J. Werring, Martina Goldlin, Marcel Arnold, Cecilia Ferrari, Seraina Beyeler, Christian Fung, Bruno J. Weder, Turgut Tatlisumak, Sabine Fenzl, Beata Rezny-Kasprzak, Arsany Hakim, Georgia Salanti, Claudio Bassetti, Jan Gralla, David J. Seiffge, Thomas Horvath, Jesse Dawson
Summary: This study aimed to compare the effect of early initiation versus later initiation of direct oral anticoagulants (DOACs) on acute ischemic stroke in patients with atrial fibrillation. The results showed that there was no significant difference in the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death within 30 days between early and later use of DOACs.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Multidisciplinary Sciences
Kimberly Saddler, Jason Zhang, Jennifer Sul, Pruthvi Patel, Miriams Castro-Lainez, Mark L. Stevens, Sheryl Kosler, Emily Lowery, Miguel Sierra-Hoffman
Summary: The study demonstrates that oritavancin provides a single-dose alternative to multi-day therapies for skin and skin structure infections, and has both clinical and economic advantages compared to other antibiotic agents in treating ABSSSI patients.